Daily Sepsis Research Analysis
Three studies advance precision sepsis care: an RNA-seq multicohort meta-analysis defines three molecular endotypes with distinct mortality risks and gene classifiers; a population-based cohort shows a strong non-linear link between blood culture time-to-positivity and severity; and a multicenter analysis finds hypoalbuminemia slows clearance with ertapenem-combination therapy for MSSA bacteremia, underscoring PK-aware prescribing.
Summary
Three studies advance precision sepsis care: an RNA-seq multicohort meta-analysis defines three molecular endotypes with distinct mortality risks and gene classifiers; a population-based cohort shows a strong non-linear link between blood culture time-to-positivity and severity; and a multicenter analysis finds hypoalbuminemia slows clearance with ertapenem-combination therapy for MSSA bacteremia, underscoring PK-aware prescribing.
Research Themes
- Precision endotyping and stratification in sepsis
- Prognostic markers from laboratory kinetics (time-to-positivity)
- Pharmacokinetic-aware antibiotic strategies in bacteremia
Selected Articles
1. Molecular endotypes in sepsis: integration of multicohort transcriptomics based on RNA sequencing.
An RNA-seq multicohort meta-analysis (n=280 discovery; n=123 validation) identified three sepsis endotypes—coagulopathic, inflammatory, and adaptive—with distinct immune signatures and mortality risks. A 14-gene classifier enabled endotype assignment and reproduced mortality patterns in an external cohort, supporting precision stratification.
Impact: Defines biologically coherent, prognostically meaningful sepsis endotypes using RNA-seq with external validation and a practical gene classifier. This framework can enrich future trials and enable targeted therapies.
Clinical Implications: Endotype-based stratification could guide risk-adapted therapies and trial design; the 14-gene classifier may be adapted into rapid assays to identify coagulopathic patients at higher mortality risk.
Key Findings
- Three RNA-seq-derived sepsis endotypes were identified: coagulopathic (30%), inflammatory (42%), and adaptive (28%).
- Coagulopathic endotype had higher mortality than adaptive in discovery (30% vs 16%; OR 2.19, 95% CI 1.04–4.78; p=0.04).
- External validation (n=123) reproduced the three endotypes and mortality pattern (34% vs 18%; p=0.10).
- Immune signatures differed: coagulopathic showed increased monocytes/neutrophils and coagulation signaling; adaptive had elevated T/B-cell composition; inflammatory upregulated TNF-α/NF-κB and IL-6/JAK/STAT3.
- A 14-gene classifier enabled practical endotype assignment across cohorts.
Methodological Strengths
- Multicohort RNA-seq integration with consensus clustering and immune deconvolution
- External validation cohort and development of a 14-gene classifier
Limitations
- Discovery sample size was modest (n=280) with potential cohort heterogeneity and batch effects
- Validation mortality difference did not reach conventional significance (p=0.10)
Future Directions: Prospective, endotype-adaptive trials and development of rapid point-of-care assays based on the 14-gene classifier; integration with proteomics and metabolomics for multi-omic refinement.
BACKGROUND: The heterogeneity of host responses in sepsis has hindered efforts to develop targeted therapies for this large patient population. Although growing evidence has identified sepsis endotypes based on the microarray data, studies using RNA-seq data-which offers higher sensitivity and a broader dynamic range-remain limited. We hypothesized that integrating RNA-seq data from patients with sepsis would reveal molecular endotypes with distinct biological and clinical signatures. METHODS: In this meta-analysis, we system
2. Association of time to positivity with disease severity in bloodstream infections-a population-based cohort study.
In 12,585 bloodstream infection episodes, shorter blood culture time-to-positivity showed a strong non-linear association with higher severity and mortality. Species-specific analyses (e.g., Enterobacterales, beta-hemolytic streptococci, S. pneumoniae, S. aureus) confirmed elevated risks, supporting TTP as a pragmatic early prognostic marker.
Impact: Clarifies conflicting literature by demonstrating an exponential TTP–severity relationship at scale and across key pathogens, enabling risk stratification from routine laboratory data.
Clinical Implications: Incorporate TTP thresholds into early triage and escalation protocols; integrate TTP with lactate and vitals to flag high-risk BSI patients for ICU-level monitoring.
Key Findings
- Shorter TTP associated with higher 30-day mortality: model estimated ~20% at 6 h and ~30% at 3 h (overall 14.4%).
- Species-specific models showed TTP linked to >30% risk of ICU admission or mortality in Enterobacterales, beta-hemolytic streptococci, Streptococcus pneumoniae, Staphylococcus aureus, and polymicrobial BSIs.
- Shorter TTP correlated with worse severity markers, e.g., lactate ~3 mmol/L at TTP 8 h and ~4 mmol/L at TTP 4 h (overall median 1.9 mmol/L).
- Median TTP was 12.1 h (IQR 9.7–17.7) across 12,585 unique BSI episodes.
Methodological Strengths
- Population-based cohort with linkage to laboratory, vital signs, ICU admission, and 30-day mortality
- Non-linear regression capturing exponential associations and species-specific analyses
Limitations
- Retrospective design with potential confounding (e.g., inoculum size, prior antibiotics)
- Generalizability may be limited outside the studied region and laboratory systems
Future Directions: Prospective validation of TTP-informed triage rules and integration into electronic alerts; cost-effectiveness analyses for resource allocation.
OBJECTIVES: Short time to positivity (TTP) has been proposed as a prognostic indicator in bloodstream infection (BSI) but results have been conflicting. The aim of this study was to explore the association between TTP and disease severity, using non-linear models. METHODS: This population-based retrospective study included all blood cultures in southern Sweden from 2021 to 2023. Using healthcare databases, BSI episodes were linked to information regarding prespecified disease severity markers at the time of culture (lab
3. Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.
In a multicenter retrospective cohort (n=100) of persistent MSSA bacteremia treated with ertapenem combination therapy, hypoalbuminemia (<2.5 g/dL) was associated with significantly longer time to blood culture sterilization after propensity score weighting (HR 0.45; p=0.001). Findings highlight protein binding and exposure concerns in low albumin states.
Impact: Provides clinically actionable evidence that hypoalbuminemia undermines the efficacy of ertapenem-combination therapy in MSSA bacteremia, informing antibiotic selection and dosing strategies.
Clinical Implications: Assess albumin before using ertapenem combinations for MSSA bacteremia; consider alternative regimens or PK-optimized dosing in hypoalbuminemia to avoid delayed clearance.
Key Findings
- After propensity score weighting, hypoalbuminemia (<2.5 g/dL) was linked to longer time to negative blood cultures (HR 0.45, 95% CI 0.27–0.72; p=0.001).
- Cohort characteristics: 100 included; 38% persons who inject drugs; 52% had definitive endocarditis.
- Standard ertapenem dosing (1 g q24h; 500 mg q24h if CrCl <30 mL/min) was used; PK studies are warranted to confirm exposure effects.
Methodological Strengths
- Multicenter design with propensity score weighting to address confounding
- Clinically meaningful primary endpoint (time to culture sterilization)
Limitations
- Retrospective design without direct pharmacokinetic measurements
- Residual confounding possible (disease severity, source control, concomitant therapy)
Future Directions: Prospective PK/PD studies to quantify ertapenem exposure in hypoalbuminemia and randomized evaluations of alternative combinations for persistent MSSA bacteremia.
BACKGROUND: Ertapenem combination therapy has been associated with a faster time to blood culture sterilization in patients with MSSA bacteraemia. However, guidance documents advise avoiding ertapenem in patients with a serum albumin level of <2.5 g/dL for Gram negative infections given that ertapenem is highly protein bound and patients with hypoalbuminemia may experience suboptimal ertapenem exposures. PATIENTS AND METHODS: This study was a retrospective, multicenter study of consecutive adult patien